Buchumschlag

Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system

Immune checkpoint inhibitors have shown efficacy in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) gastrointestinal (GI) cancers. However, depth and duration of clinical response is not uniform. We assessed tumor mutation burden (TMB) as a response marker in pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hirsch, Daniela (VerfasserIn) , Gaiser, Timo (VerfasserIn) , Merx, Kirsten (VerfasserIn) , Weingärtner, Simone (VerfasserIn) , Forster, Michael (VerfasserIn) , Hendricks, Alexander (VerfasserIn) , Woenckhaus, Matthias (VerfasserIn) , Schubert, Thomas (VerfasserIn) , Hofheinz, Ralf-Dieter (VerfasserIn) , Gencer, Deniz (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2020
In: Journal of cancer research and clinical oncology
Year: 2021, Jahrgang: 147, Heft: 1, Pages: 263-273
ISSN:1432-1335
DOI:10.1007/s00432-020-03335-2
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00432-020-03335-2
Volltext
Verfasserangaben:Daniela Hirsch, Timo Gaiser, Kirsten Merx, Simone Weingaertner, Michael Forster, Alexander Hendricks, Matthias Woenckhaus, Thomas Schubert, Ralf-Dieter Hofheinz, Deniz Gencer
Beschreibung
Zusammenfassung:Immune checkpoint inhibitors have shown efficacy in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) gastrointestinal (GI) cancers. However, depth and duration of clinical response is not uniform. We assessed tumor mutation burden (TMB) as a response marker in patients with GI cancers treated with immune checkpoint inhibitors.
Beschreibung:Published: 09 August 2020
Gesehen am 02.06.2021
Beschreibung:Online Resource
ISSN:1432-1335
DOI:10.1007/s00432-020-03335-2

Ähnliche Einträge